Ligand to Hold Investor and Analyst Day on December 13
Ligand Pharmaceuticals (NASDAQ: LGND) will host an Investor and Analyst Day on December 13, 2022, from 11:00 a.m. to 12:30 p.m. Eastern time in New York. The event will feature key executives including CEO John Higgins and CFO Tavo Espinoza. Topics will cover Ligand's business model, financial outlook, and technology platforms. A live webcast will also be available. Ligand is focused on developing technologies to support pharmaceutical companies, leveraging a diversified portfolio to reduce risks and enhance shareholder value.
- Upcoming Investor and Analyst Day set for December 13, 2022, allowing for engagement with investors.
- Presentation of Ligand's business model and financial outlook which could provide insights for investors.
- Showcasing of advanced technology platforms that may enhance revenue-generating potential.
- None.
-
John Higgins , Chief Executive Officer -
Matt Korenberg , President and Chief Operating Officer -
Tavo Espinoza , Chief Financial Officer -
Andrew Reardon , Chief Legal Officer -
Diane Retallack , Senior Vice President of Platform Technology and Innovation
Presentations by Ligand executives will address the following topics:
- Commentary on Ligand’s business model, financial outlook and capital deployment strategy
- Overview of Ligand’s technology platforms
- Overview of core partner and license assets
- Review of Ligand’s intellectual property and patent portfolio
- Discussion of Ligand’s commitment to ESG and ongoing corporate sustainability initiatives
The presentations will be followed by lunch for those attending in person. The live and archived webcast can be accessed here. For more information or make a reservation to attend, please contact
About
Ligand is a biopharmaceutical company focused on developing or acquiring technologies that help pharmaceutical companies discover and develop medicines. Our business model creates value for stockholders by providing a diversified portfolio of biotech and pharmaceutical product revenue streams that are supported by an efficient and low corporate cost structure. Our goal is to offer investors an opportunity to participate in the promise of the biotech industry in a profitable, diversified and lower-risk business than a typical biotech company. Our business model is based on doing what we do best: drug discovery, early-stage drug development, product reformulation and partnering. We partner with other pharmaceutical companies to leverage what they do best (late-stage development, regulatory management and commercialization) ultimately to generate our revenue. Ligand’s Captisol® platform technology is a patent-protected, chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. Ligand’s Pelican Expression Technology® is a robust, validated, cost-effective and scalable platform for recombinant protein production that is especially well-suited for complex, large-scale protein production where traditional systems are not. Ligand has established multiple alliances, licenses and other business relationships with leading pharmaceutical companies including Amgen, Merck, Pfizer, Takeda, Gilead Sciences and Baxter International. For more information, please visit www.ligand.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221116005413/en/
investors@ligand.com
(858) 550-7766
LHA Investor Relations
bvoss@lhai.com
(310) 691-7100
Source:
FAQ
What will Ligand Pharmaceuticals discuss during the Investor and Analyst Day?
Who are the presenters at the Ligand Pharmaceuticals Investor Day?
When is the Ligand Pharmaceuticals Investor and Analyst Day event?
Where can I access the Ligand Pharmaceuticals Investor Day webcast?
What is the focus of Ligand Pharmaceuticals as a biopharmaceutical company?
